Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2012 Publisher: Aspen Pharma Trading Limited 12/13 Exchange Place I.F.S.C Dublin 1 Ireland
Lanoxin 125 Tablets.
Pharmaceutical Form |
---|
Tablet. |
Digoxin Ph Eur 0.125 mg/tablet
Active Ingredient | Description | |
---|---|---|
Digoxin |
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. |
List of Excipients |
---|
Lactose Ph Eur |
Amber glass bottle with low-density polyethylene snap-fit closure
Pack sizes: 28, 50, 500 tablets
Amber glass bottle with a clic-loc child resistant closure
Pack size: 56 tablets
White opaque PVC/aluminium foil blister
Pack sizes: 30, 60, 90, 120 tablets
Not all pack sizes may be marketed.
Aspen Pharma Trading Limited
12/13 Exchange Place
I.F.S.C
Dublin 1
Ireland
PL 39699/0009
24 April 2003
Drug | Countries | |
---|---|---|
LANOXIN | Australia, Cyprus, Hong Kong, Ireland, Israel, Lithuania, Malta, Mexico, Netherlands, New Zealand, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.